Patrick Campbell

An analysis of more than 180k patients in Hong Kong indicated use of the antihypertensive medications was associated with 22% lower risk of developing colorectal cancer.

A new pilot study called CRAFT is examining the potential of portable air cleaners for limiting exposure to fine particulate matter in patients enrolled in cardiac rehabilitation.

New analysis of the Jackson Heart Study found experiencing a greater amount of discrimination could increase risk of hypertension in African Americans.

A systematic review and network meta-analysis is comparing 9 classes of therapies for HbA1c and risk management in patients with low versus increased cardiovascular risk.

Results of a new study suggest patients who undergo congenital heart surgery during youth have an increased risk of cardiovascular disease, endocrine disease, and psychiatric disease.

A new analysis of more than 47 million person-years of data indicates women who delivered a baby preterm were at a greater risk of developing ischemic heart disease.

Results of the FABOLUS-FASTER trial indicate tirofiban may be more effective than cangrelor in reducing risk of acute ischemic complications when used for bridging platelet inhibition in heart attack patients undergoing percutaneous coronary intervention.

New research from an analysis of the Swedish Medical Birth Registry suggests women experience preterm delivery were at an increased risk of developing ischemic heart disease later in life.

A new analysis of more than 260 children is shedding light on associations between blood pressure and ophthalmic issues later in life.

A new randomized trial suggests oral apixaban may be as effective as enoxaparin for thromboprophylaxis following surgery for gynecologic cancer.

Results of the FABOLUS-FASTER trial offer clinicians further insight into the effects of cangrelor, tirofiban, and chewed or integral prasugrel for immediate inhibition of platelet aggregation.

Data from a simulation performed by investigators from Harvard Medical School is detailing the potential losses in revenue primary care practices are expected to experience in 2020.

Results of a first-in-man trial suggests a non-invasive ultrasound therapy improved cardiovascular health in patients with severe calcific aortic stenosis (CAS).

A new systematic review and meta-analysis is shedding light on the impact gestational hypertension can have on future risk of cardiovascular diseases.

An analysis of data from a trio of phase 3 trials suggest use of the novel osteoporotic treatment could increase risk of heart attack by 18%.

Results of an exploratory analysis of the phase 3 MARINER study indicates post-discharge prophylaxis with rivaroxaban (Xarelto) could reduce the risk of both fatal and major thromboembolic events in medically ill patients.

An analysis of the MARINER trial is diving deeper into the impact of post-discharge prophylaxis with rivaroxaban in patients with more severe renal impairment.

New research suggests the microbiome from the tongue coating of patients with heart failure contains unique differences to those of healthy patients.

While often referred to as "Good cholesterol" new research suggests HDL measurements do little for predicting risk of heart attack in Black patients

A new study found newly diagnosed type 2 diabetics who develop heart failure had the highest risk of death versus patients with other CVDs or chronic kidney disease.

New research suggests development of heart failure is associated with the greatest risk of death among type 2 diabetics with cardiovascular conditions.

New research from ARVO 2020 suggests patients with diabetic eye disease can still experiences losses in visual acuity, even with glycemic control.

A survey of 19 patients with hereditary retinitis pigmentosa details the impact of the disease on the quality of life and daily activity of patients and caregivers.

New research suggests signs a person may be more susceptible to type 2 diabetes later in life are visible in children as young as 8 years old.

The FDA's approval of insulin lispro-aabc injection is based on the results of 2 phase 3 trials—PRONTO-T1D and PRONTO-T2D.

Crysvita received approval from the FDA for treatment of TIO in patients aged 2 years and older.

Both type 1 and type 2 diabetics now have an additional insulin option available to them in the form of insulin lispro-aabc injection (Lyumjev) 100 units/mL and 200 units/mL.

New research from Penn Medicine indicates 9.6% of heart surgery patients develop persistent opioid use post-procedure.

A nationwide analysis indicates stroke patients in rural areas were at a greater risk of mortality and less likely to receive advanced treatment than urban counterparts.

A pooled analysis of 5 PIONEER trials presented by John Buse, MD, at ADA 2020 is shedding new light on the impact of oral semaglutide based on background glucose-lowering therapy.